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ABSTRACT
Multiple Myeloma (MM) is a malignancy characterized by the hyperdiploid (HD-
MM) and the non-hyperdiploid (nHD-MM) subtypes. To shed light within the molecular 
architecture of these subtypes, we used a novel integromics approach. By annotated 
MM patient mRNA/microRNA (miRNA) datasets, we investigated mRNAs and miRNAs 
profiles with relation to changes in transcriptional regulators expression. We found 
that HD-MM displays specific gene and miRNA expression profiles, involving the 
Signal Transducer and Activator of Transcription (STAT)3 pathway as well as the 
Transforming Growth Factor–beta (TGFβ) and the transcription regulator Nuclear 
Protein-1 (NUPR1). Our data define specific molecular features of HD-MM that may 
translate in the identification of novel relevant druggable targets.
INTRODUCTION
Multiple myeloma (MM) is a lethal disease of 
antibody-secreting bone marrow plasma cells (PCs) that 
accounts for 10% of all hematological neoplasias with 
worldwide increasing incidence. MM is characterized 
by a wide clinical spectrum ranging from the pre-
malignant condition called monoclonal gammopathy 
of undetermined significance (MGUS), to smoldering 
MM, truly overt and symptomatic MM, and finally extra-
medullary MM/plasma cell leukemia (PCL). Despite 
the recent remarkable improvement in the treatment 
and patient care, the availability of novel therapeutic 
strategies and investigational platforms, MM remains 
an incurable disease [1-11]. In the last decade, important 
advances in molecular cytogenetics and global genomic 
studies brought about a significant advancement in the 
comprehension of MM pathogenesis [12-14]. Nearly half 
of MM tumors are defined as hyperdiploid (HD-MM) 
associated with copy number alterations, such as trisomies 
of odd chromosomes (3,5,7,9,11,15,19,21). The remaining 
tumors are referred as non-hyperdiploid (nHD-MM) and 
are frequently associated with constitutive activation of 
genes, such as CCND1 (11q13), CCND3 (6p21), MAF 
(16q23), MAFB (20q11), or FGFR3/MMSET (4p16.3), 
as a result of chromosomal translocations involving the 
immunoglobulin heavy chain locus (IgH) on chromosome 
14q32. Even though the genetic characterization of HD-
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MM and nHD-MM is well established at both mRNA or 
miRNA levels [15-19], there is still scope for an integrated 
deep analysis of whole molecular profiling data to disclose 
transcriptional networks of HD-MM. Li et al [20] have in 
fact hypothesized that chromosome alterations imprint the 
gene expression by dosage effect and developed a method 
for MM classification with a deeply comprehension of the 
disease biology and prognosis of HD-MM and nHD-MM 
subtypes, reinforcing the rationale of our investigation. 
In the last decade, the role of miRNAs as post-
transcriptional regulators has been widely investigated. 
Deregulation of their expression has been associated 
with several diseases including cancer. Nonetheless, 
the elucidation of the mechanisms underlying miRNA 
involvement in MM pathogenesis is still an unmet goal. 
Our experimental strategy relies on novel integrative 
genomics approaches, which integrate data from different 
genomic levels (mRNA, miRNA, transcription factors, 
genetic aberrations, methylomics and others) with clinical 
data, providing a comprehensive view of underlined 
biology [21-23]. Existing approaches span from the 
application of classical fold-change analysis of miRNA 
expression data to the application of complex models 
of integration of miRNA and mRNA expression data 
into single networks. However, these latter strategies 
may suffer from several drawbacks: (i) the existence 
of many false positive miRNA targets, (ii) the lack of 
comprehension of downstream mechanisms, and (iii) 
the presence of feedback and feed-forward loops among 
miRNAs and genes. Recent findings clearly support the 
notion that interconnecting miRNAs with transcription 
factor (TF) genes and other upstream regulators (URs) 
may be of major help for the elucidation of oncogenetic 
and progression events [24]: consequently, several novel 
approaches have been devoted to the investigation of 
relations among miRNAs, expression of target genes and 
transcription factors [25]. To this aim, traditional gene-
set-enrichment tools [26] have been partially substituted 
by more sophisticated models based on a system-level or 
semantic-based analysis [27, 28], and data interpretation 
by the integration with prior biological knowledge, into 
the workflow of analysis, e.g. the use of causal networks 
(i.e. networks that explicitate the causal relationships) 
[29, 30]. Based on the ability to retrieve the direction of 
interactions among genes (including mutual feed-forward 
loop), causal analysis is more efficient than classic 
enrichment methods. To date, different approaches have 
been described for casual analysis [21]: herein, we selected 
those that have been implemented into the Ingenuity 
Pathway Analysis® (IPA) platform [31]. Specifically, we 
performed our analysis starting from the hypothesis that 
trisomies associated with HD-MM may extensively affect 
miRNAs, transcription regulators (TRs) and target gene 
expression in this subset of patients. To this aim, we took 
advantage of IPA analysis and paired miRNA and gene 
expression data from a recently published dataset [16]. 
Our approach has been based on a novel 3-step strategy: (i) 
identification of differentially expressed mRNA/miRNAs, 
(ii) identification of regulatory networks in which these 
genes were involved, by using prior-biological knowledge 
stored on IPA, and (iii) overlapping of miRNA regulatory 
class with regulatory network data. The final goal is the 
identification of reliable upstream biological causes and 
downstream effects, in order to depict the main functional 
features embedded in the HD-MM genomic architecture.
RESULTS
Differential expression analysis
We analyzed the paired mRNA/miRNA microarray 
data included in a public available dataset of MM patients 
at diagnosis from a well-characterized clinical trial [16], 
aimed at elucidating the UR mRNA-miRNA circuitry 
depicted in HD-MM versus nHD-MM. The workflow of 
data processing and analysis is outlined in Figure 1. After 
pre-processing of raw data using Affymetrix tools, we 
used dChip software to filter possible outlier genes and 
miRNAs and to compare the two MM subgroups.
The clustering analysis was performed to elucidate 
the differences between the two classes on gene and 
miRNA expression. The heat-maps in Figure 2 and 
supplementary information indicate two main groups 
that include almost HD-MM in the right branch and the 
nHD-MM mainly clustered in the left branch, supporting 
our aim to further analyze these differences in deep. 
Consequently, we generated the lists of significantly 
differentially expressed (SDE)-genes and miRNAs in 
HD-MM. Our data are in line with previous evidence 
[15-18, 20], indicating that HD-MM are characterized 
by distinct transcriptional profiles, likely associated 
with the specific chromosomal alterations. Then, we 
annotated SDE-genes on the basis of known associated 
pathways and molecular functions, in order to discard 
uninformative transcripts. The IPA analysis identified the 
top 20 canonical pathways related to SDE-genes (Figure 
3). Among the most modulated pathways, we found high 
perturbation of the Signal Transducer and Activator of 
Transcription (STAT)3 pathway (-Log(p-value)=3.5) 
together with other signaling pathways involved in cell 
proliferation and survival or intracellular signaling 
including PTEN, IL-8 and ERK/MAPK signaling (Figure 
3A). By canonical pathway analysis, we found among 
all the SDE-genes, a subset known as involved in some 
important pathways. Indeed we found that SDE-genes 
identified in previous step are related to STAT3 pathways 
including genes involved in cell cycle progression (Cyclin 
D1, D2, and c-Myc), cell survival (Bcl-xL, Bcl-2, Mcl-1), 
angiogenesis (HIF1α, VEGF), cancer inflammation (NF-
KB, IL-6). These findings confirm the initial hypothesis 
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Figure 1: Overview of the workflow used in the analytical model. A.-B. Microarray available data-sets published by Wu et al. 
were the basic material for all analysis. After the initial preprocessing conducted by Affymetrix proprietary software, we filtered data using 
DChip. Supervised analysis identified significant differentially expressed (SDE) mRNA and miRNA by comparing two annotated groups 
hyperdyploids (HD-MM) versus non hyperdyploids (nHD-MM) multiple myeloma obtaining two different SDE lists: i) SDE-genes and ii) 
SDE-miRNAs. C. IPA software was used to perform: i) functional analysis (canonical pathways and bio-functions), carried out by SDE-
genes and miRNAs to identify biological events related to the two MM subtypes; ii) miRNA target filter, performed by the SDE-miRNAs 
to select experimental or high confidence predicted target annotated in IPA base; iii) upstream regulator analysis (URA), integrated gene 
expression data into IPA software to identify URs related to the identified transcription events. D. Overlapping of prior knowledge inferred 
by IPA with experimental data (transcriptional and post-transcriptional) to identify miRNA-transcription regulators interplay and Circos 
Plot representation to visualize miRNA-gene anti-correlations and inference of the biological behavior in the MM disease. 
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of a highly differentiated molecular scenario in HD-MM 
versus nHD-MM.
In silico functional annotation
Functional annotations of SDE-miRNAs revealed 
main biological functions related to HD-MM versus nHD-
MM. To better understand the hidden biology in complex 
‘omics’ datasets, IPA provides insights into the molecular and 
chemical interactions and cellular phenotypes of the disease 
process. We found that the most significant functions that 
differentiated the two subtypes of MM patients were 
annotated as “cell growth and proliferation”, “cellular 
development” and “cell death” based on SDE-mRNAs 
(genes). Similarly, the same functional analysis performed 
on SDE-miRNAs revealed an overlapping scenario 
(supplementary information).
Upstream regulator analysis
The IPA Knowledge base contains a large collection 
of experimental observations and findings obtained 
by integrating different data-sources including both 
biomedical literature and other databases. Consequently, 
IPA provides an underlying graph with more than 40.000 
nodes (representing genes, proteins, miRNA, and other 
biologically active molecules and functions) and more 
than 1.400.000 edges representing different relations (e.g. 
causal relationships, or other effects related to expression, 
transcription, activation, molecular modification and 
transport). The knowledge base is used to perform the 
UR analysis (URA). In particular the algorithm embedded 
into IPA, determines likely URs (i.e. genes or molecules) 
that provide the regulation of the expression, analyzing 
the connections among such nodes and genes included in 
the dataset under investigation. The goal of URA is the 
understanding of regulatory mechanisms involved in data 
expression changes. In such a way URA is a powerful tool 
since the inference of URs allows the identification of 
potentially disrupted or altered mechanisms of regulators 
that may disclose potential druggable targets. 
It must be underlined that URs do not necessarily 
represent TFs or other direct transcription regulators. 
URA tries to overcome the main limitations of classical 
approaches that are able to individuate SDE-genes and 
their related functions but lack in the individuation of 
causative relationship. By using URA, we may highlight 
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causes of differential expression: i) TFs or TRs (upstream 
regulators, URs) known to modulate genes (identified as 
SDE-genes) based on Ingenuity embedded knowledge and 
ii) miRNAs experimentally identified as SDE-miRNAs in 
HD-MM vs nHD-MM patients that inhibit URs and their 
target genes. Moreover, we may also explain the effects of 
different modulation in terms of involved and downstream 
regulated targets. 
Considering the overall scenario of Network 
Based Analysis, it should be noted that the main related 
approaches are MAGIA, mirConnX, dChipGemini, 
mirconnX and the previous Connectivity Map tool [32] 
that integrate mRNA and miRNA data and provide the 
analysis of regulatory networks.
With respect to those algorithms, it should be 
underlined that our approach has some advantages: i) IPA 
has a larger knowledge base that is periodically updated 
compared to the other approaches; ii) IPA offers the 
possibility to analyze even downstream effects, while 
other approaches analyze only regulatory mechanism 
among TF, miRNA and mRNA. Moreover, other tools 
such as PARADIGM, lack the possibility to explore 
the functional biology, considering that they offers the 
possibility to integrate only gene expression and copy 
number data.
Based on the differential gene expression data, URA 
identified 3 significant mechanisms. First, we identified 
the activation of NUPR1 TF as candidate regulator of a 
defined set of down-regulated (BNIP3, GINS1, GRAMD3, 
KIF11, SHCBP1 SPIN4) or up-regulated (ELMOD1 
and SLC16A6) genes, according to our gene expression 
data (Figure 3B and Table S1). The other mechanism 
Figure 2: mRNA and miRNA signatures for hyperdiploid MM classification. Heat maps showing the filtered mRNAs A. or 
miRNAs B. obtained by DChip Software. The genetic characteristics are reported including hyperdiploid status indicated as 1=HD-MM 
and 2=nHD-MM, N=not available and genetic alteration presence (1) or absence (2). Then standardized expression values (mean= 0, SD 
=1) for each molecule were analyzed through hierarchical clustering in DChip in order to show groups of mRNA and miRNA with similar 
expression changes. Clustering uses the Spearman correlation test between genes and samples and serves as the basis for merging nodes and 
building hierarchical trees. Finally clustered data were visualized through heat-maps. Colors represent respectively the down-regulation 
(scales of blue) and the up-regulation (scales of red). The standardized expression values most likely fall within [-2, 2]. By default, DChip 
uses pure white to represent 0, pure red to represent 2 or higher, and pure blue to represent –2 or lower.
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Figure 3: Functional Analysis. A. Top 20 signaling pathways identified by IPA include 39 selected molecules. The significance of 
association between selected genes and canonical pathway was evaluated by a scoring Fisher’s Exact Test p-value (bars upper threshold 
line on y-axis). The ratio referring to the proportion of selected genes that matched the total number of molecules annotated in the related 
pathway (square dot line on the bar graph, bottom y-axis). The height of the bar represents the –log(p-value), thus is directly proportional 
to the statistical significance. B. Figure represents molecules involved in upstream regulator analysis integrated in a single networks. Figure 
shows upstream regulators (NUPR1, TGFB1, TP73 and HIC1) their target genes as nodes of the network and relationships among them as 
edges. A gene is painted in red when it has been identified as up-regulated (i.e. over-expressed as revealed by fold-change analysis) while 
it painted in green when it is down-regulated. Each arrow links two genes whose the regulator mechanism is known. Arrows indicate both 
inhibition and activation through different colors. Yellow arrows indicate that the behavior of those genes in our dataset is divergent from 
what should be as predicted on a priori knowledge, and therefore needs additional investigation.
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highlighted by URA integrates the regulators TGFB1, 
TP73 and HIC1. As for NUPR1, TGFB1 appears to be 
activated and different molecules related to this growth 
factor show expression as predicted by IPA analysis 
(Table S1). On the other hand, HIC1 and TP73 should 
be inhibited based on the down-regulation of the target 
molecules including SPP1, CCNE2 and FAS. It is possible 
to appreciate that the activation or inhibition of the upper 
listed set of genes account properly in the our mRNA-
SDE analysis. We also report an inconsistent finding 
among our experimental results and the prior knowledge 
about TP73 and TGFB1 relations. In fact, it is reported 
that TP73 activate TGFB1 expression [33], while in our 
dataset the inhibition of TP73 is inconsistent with the 
activation of TGFB1 clearly underlying the need of further 
investigations.
In order to better explain the functions carried 
out by these genes, we performed a functional analysis 
using as input only URs and related targets and we depict 
the enriched functions by overlapping these to the prior 
networks shown in supplementary information. In each 
figure, we show different enriched functions and we 
highlight corresponding molecules by evidencing them 
with a different border. Enriched functions are related 
to “cell growth” (Figure 2S-A), “cell cycle progression” 
(Figure 2S-B) and “tissue development” (Figure 2S-C). 
Since all these functions may be related to different cell 
progression behavior.
miRNA-TR interplay
Integration of miRNA-target has been performed by 
IPA based on experimental and high confidence prediction 
using sources including Tarbase, TargetScan and IPA 
internal findings. In our method, we overlapped the prior 
knowledge obtained by URA analysis with experimentally 
observed data as deregulated miRNAs. The results of 
integration between SDE-miRNAs and targets, including 
inferred URs and relative targets detected as SDE-mRNA, 
are represented in Figure 4. Here, all relationships are 
in agreement with the model “miRNA inhibits targets”. 
In fact, considering the NUPR1 inferred activation, two 
different down-regulated miRNAs were detected, miR-
125b and miR-34c, targeting SLC16A6 and ELMOD1, 
respectively. Both genes are up-regulated and may explain 
the activation of the NUPR1. On the other hand, miR-590-
3p, which is up-regulated, may cause down-regulation of 
its target GRAMD3 and similarly up-regulation of miR-
590-5p may induce down-regulation of SHCBP1. On 
this last, it may exerts its inhibitory effect also the miR-
520c-3p, that we detected as up-regulated in our model. 
Thus, the interplay miRNAs-URs-targets depicts a new 
Figure 4: miRNA-TR interplay. The network represents the integration of upstream regulator inference and miRNAs. Global 
regulatory network includes miRNAs and their targets selected between the top 4 URs and respective inferred genes. The nodes are URs 
with different shape for each function, colored orange or blue respectively for activation or inhibition. Circle are used for target signature 
genes. miRNAs and genes are colored in red or green as according for up- or down-regulation as reported in the SDE-genes and miRNAs 
lists. Connections between main players of the global regulatory network are depicted by lines where the relationships between miRNAs 
and target genes are shown as dashed lines with inhibitory function, while relationships between TRs and target genes are presented by lines 
either indicating activation or repression.
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regulatory scenario that differentially characterizes the 2 
MM subgroups. In addition, over-expression of different 
miRNAs, including miR-130a and miR-590-5p, and the 
inferred activation of TGFB1 may explain the down-
regulation of FAS. Similarly, up-regulation of miR-520c-
3p detected in the HD-MM may causes inhibition of TP73 
and CCND2. The latter are strongly down-regulated in 
HD-MM also for the inhibitory activity induced by over-
expression of miR-520c-3p, miR-526b and miR-135a. 
Conversely, low expression of miR-30c and miR-361-3p 
in HD-MM may explain the up-regulation of PTPRK and 
CTGF genes. Finally, we observed that inhibition of TP73 
could be also affected by the over-expression of miR-142-
3p and miR-130a and all together may induce a strong 
down-regulation of PMAIP1 as detected in HD-MM cases. 
We have used Circos plot to integrate data and 
results obtained by IPA. We combined in a single graph 
mRNA, miRNA, URA and biological functions. In this 
way, we easily visualized the putative interactions of URAs 
and miRNAs on same target (Figure 5). We identified 9 
miRNAs as most important post-transcriptional regulators 
of the URs. Most of them (5) direct regulate TP73 and 
downstream effectors together with many genes (FAS, 
TGIF1, PLK2, PMAIP1) that in turn reflect their inhibitory 
effect on all described networks. 
Figure 5: Circos Plot. The circos diagram visualize the dependency of the transcriptome represented in the form of top biological 
functions and of inferred upstream regulators: miRNAs, TRs and target mRNAs. The width of categories depends of the number of member 
molecules. In the circos plot we display these molecules with a segment and each connection with a ribbon. A connection between a TR 
and biological function means that this molecule was detected as activated or inhibited UR by upstream regulator analysis and that its target 
genes identified as SDE-genes grouping in the same functional category. A connection between a miRNA and a gene implies that this was 
the miRNA and its predicted target are regulated by UR. Finally, a connection between a gene and a biological function indicates it has 
annotation in the specific functional category. The Circos integrate all the relevant findings of the model we employed.
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DISCUSSION
The major aim of our work was to disclose the 
dynamic connection between the differential miRNome 
and transcriptome of the HD-MM versus nHD-MM. By 
a novel integrative genomic approach, we focused on the 
interplay of miRNAs, URs and target genes expression in 
the 2 subgroups on a comparative analysis. Recent reports 
highlight the relation between the genetic background 
of HD-MM or nHD-MM and the different clinical 
phenotypes, even if the genetic landscapes remain mostly 
undefined; nHD-MM is indeed defined on exclusion 
of HD and it is therefore a heterogeneous condition. 
Our experimental approach was an in silico functional 
analysis based on the transcriptomic (gene expression 
profiling) and the miRNomic background of HD-MM with 
nHD-MM patients. HD-MM patients showed significant 
gene and miRNA expression differences with nHD-
MM patients based on heat maps reported (Figure 2 and 
supplementary materials), according to the knowledge 
that primary genetic events contribute to plasma cell 
immortalization and define the classification of MM. 
Prognostic subgroups have been defined using signatures 
derived from gene expression profiling [34, 35]. In this 
context the discovery of miRNA networks has revealed 
a new biological complexity. Also miRNA profiling has 
provided novel tools for disease stratification [16, 17, 
36, 37]. However, these approaches do not capture all 
variability of clinical behaviors since they have been 
mainly designed for prognostic purposes and not for 
analysis of biologic complexity on multiple-level of 
interaction.
Based on the miRNA and gene expression data, 2 
different branches are typically defined by hierarchical 
clustering profiles, identifying mostly HD-MM and nHD-
MM subgroups. Gene expression by itself can identify 
HD-MM as recently described [20]. We here try to 
overcome the limitations of clustering-based approaches, 
which are able to define the differences between 2 classes 
in terms of different expression levels only, by the 
search of possible causes of these differences in terms 
of interplay of miRNAs and mRNAs. To this aim, we 
performed URA that enables a “system-level” point of 
view that may be used as first step for further analysis 
(e.g. the individuation of candidate targets for drugs). 
Classical gene expression analysis has demonstrated its 
effectiveness for diagnosis and prognosis of cancer by 
individuating different molecular subtypes with different 
clinical behavior. However, all these analyses lack on 
the individuation of causes, i.e. individuation of those 
genes that are directly related to cancer progression. The 
results of our integrated analysis suggest the possible 
effect of a subset of miRNAs and URs on a common set 
of targets and offer the opportunity of further orthogonal 
investigation of TGFB1 and TP73 interactions in HD-MM. 
In this view, the integrated analysis is the first step for 
the design and development of novel therapeutics based 
on information derived from integration and functional 
Figure 6: Dinamic features of STAT3 pathway in HD-MM. Representation of the factors associated with the JAK-STAT pathway, 
detected by IPA analysis. The up-regulation of RAC1, a member of the Rho-GTPases family, induces STAT3 activation through an indirect 
feed-forward mechanism that involves the autocrine production and action of IL-6, a known mediator of STAT3, by the RAC1-mediated 
activation of MKK-JNK signaling. This circuitry establishes a link between oncogenic GTPase activity and Janus kinase-STAT signaling 
in HD-MM.
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analysis of real-world data.
Among the top modulated canonical pathways in 
HD-MM, we first identified STAT3 signaling, which is 
known to play an important role in MM-genesis through 
the regulation of growth and survival of MM cells. In 
particular, our analysis shows an up-regulation of RAC1, a 
member of the Rho-GTPases family, implicated in many 
cellular processes that influence cell proliferation, survival, 
motility and adhesion [38]. RAC1 is able to induce STAT3 
activation through an indirect feed-forward mechanism 
that involves the autocrine production and action of IL-6 
(Figure 6), a known mediator of STAT3, thus establishing 
a link between oncogenic GTPase activity and Janus 
kinase-STAT signaling [39]. Moreover, IPA upstream 
analysis revealed inhibition of HIC1, a tumor suppressor 
p53-activated gene located at chromosome 17p13.3, a 
region frequently deleted and epigenetically silenced in 
a variety of human cancers [40]. In addition to the DNA 
binding-mediated target gene regulation, HIC1 could act 
via protein-protein interactions, inhibiting several cellular 
pathways including JAK-STAT. In fact, HIC1 interacts 
with the DNA binding domain of STAT3 attenuating 
STAT3-mediated transcription of several genes [41]. 
On this basis, the increased activity of STAT3 signaling 
in HD-MM, may also rely on down-regulation of HIC1 
shown in these patients. Another important downstream 
target of HIC1 is SPP1, also known as Osteopontin 
(OPN), which is found down-regulated by our analysis 
as a possible effect of the loss of activity of HIC1. OPN 
is a multifunctional bone matrix glycoprotein [42, 43], 
whose production in MM cells plays a critical role in bone 
disease by protecting the skeleton from destruction [44]. 
This finding indicates a potential cause of the described 
prevalence of bone disease in HD-MM patients which 
have low levels of OPN.
Among the TRs which result deregulated by 
IPA upstream analysis, the transforming growth factor 
(TGFβ) plays a key role in both HD-MM and nHD-MM 
pathogenesis. TGFβ family of growth factors controls 
a number of cellular responses and acts prominently in 
development and homeostasis of most human tissues. 
Disruption of the TGFβ pathway has been implicated in 
many human diseases, including solid and hematopoietic 
tumors. As a potent inhibitor of cell proliferation, TGFβ 
acts as a tumor suppressor; however in tumor cells, 
TGFβ loses anti-proliferative response and becomes an 
oncogenic factor [45]. In our analysis TGFβ is up-regulated 
in HD-MM, suggesting that in these patients it acts as an 
oncogene [46]. Moreover, hyper-activation of this pathway 
provides another potential mechanism of the frequency of 
bone disease in HD-MM group. In fact, TGFβ enhances 
proliferation of osteoblast progenitors and promotes 
mineralization of bone matrix, but at a later stage, TGFβ 
inhibits the late phases of differentiation of osteoblasts and 
represses mineralization of matrix [47]. Conversely, in 
nHD-MM patients, TGFβ acts mostly as tumor-suppressor 
because it’s down-regulation is associated, in our model, 
with the up-regulation of FAS and CCND2. It is well 
known that Fas-mediated apoptosis plays an important 
role in activation-induced cell death, T-cell-induced 
cytotoxicity, immune privilege, tumor surveillance [48] 
and can also mediate a variety of non-apoptotic activities 
especially during tumor-genesis and tumor progression 
in Fas-resistant tumor cells [49]. In fact, Fas signaling is 
proposed to convert from a tumor suppressing to a tumor 
promoting activity, directly promoting apoptosis-resistant 
cancer cell growth and invasion [50]. Additionally, 
Fas signaling activation can induce secretion of pro-
inflammatory cytokines and chemokines [51]. It was also 
described that Fas signaling promote lung cancer growth 
by recruiting myeloid-derived suppressor cells (MDSCs) 
in vivo [52] and the bioactive Fas ligand (FasL) released 
by activated T cells in exosomes promotes melanoma 
and lung cancer cell metastasis through Fas signaling. 
Therefore our data indicate that targeting Fas signaling 
and at the same time Fas signaling-initiated cancer-related 
inflammation may be helpful as a cancer therapeutic 
strategy in MM patients. This issues clearly needs to be 
further explored in follow-up studies. Although Cyclins 
D are the class of cell-cycle regulators more involved in 
MM pathogenesis, our analysis shows up-regulation of 
Cyclin E2 which is related, with an effect not predicted 
by IPA, to downregulation of HIC1. Finally, NUPR1, a 
protein related to the high mobility group of TRs that is a 
key player in the cellular stress response and is involved 
in metastasis, is activated in HD-MM patients according 
to the target activation or inhibition. Among them BNIP3 
(down-regulated in HD-MM), a downstream target of 
NUPR1, is a novel hypoxia-inducible pro-apoptotic 
mitochondrial member of the Bcl-2 family which acts as 
tumor-suppressor by regulating apoptosis in normal and 
malignant cells [53, 54]. At present the targets identified 
by our analysis are not exploited in the current treatment 
of MM.
In summary, our work confirms that miRNome and 
trascriptome of nHD-MM is different from HD-MM. 
These findings clearly support the hypothesis that HD-MM 
and nHD-MM do not differ only in early promoting events 
(mitotic crisis in HD-MM versus mostly translocations in 
nHD-MM), but evolve by different pathways which finally 
depict a highly divergent genetic architecture which is 
based on a branched Darwinian evolution [12]. Finally, 
our findings also suggest that several druggable targets 
are predominant in HD-MM and indicate new therapeutic 
strategies to be pursued in the next future. In particular, 
aberrant STAT signaling, as previously discussed, is 
recognized as a master regulator of tumor processes 
including proliferation, apoptosis, invasion, angiogenesis 
and cancer inflammation. Therefore, hyperactivity of 
STAT3 in HD-MM suggests an important therapeutic 
target for several STAT3 inhibitors, including peptide-
mimetics, small molecule inhibitors and oligonucleotides, 
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presently in pre-clinical and clinical development [55, 
56]. Furthermore our analysis shows that TGFβ could 
be considered as a therapeutic target to disrupt the 
pathognomonic skewed cellular interactions in MM 
bone marrow microenvironment in the aim to antagonize 
bone destruction and MM-related bone disease. All these 
findings on miRNA interactions with mRNAs and URs, 
might acquire additional importance taking into account 
their relevance as therapeutic targets/agents as recently 
reported in MM [57-73]. Integrative genomics may offer 
a reliable powerful tool to select molecular targets for 
therapeutic interventions. 
For further multiple level analysis, the integration 
of RNA expression data and proteomic profiling and/or 
DNA methylation data, may drive to the identification 
of pathways predictive of favorable response and 
microenvironment interactions with clinical relevance 
in MM treatment [74, 75]. In addition, the integration of 
genomic sequencing and mutational profiling may provide 
the genomic landscape underlying MM development and 
indicates potential druggable targets in this malignancy. 
This approach is likely to outperform single level analyses 
as for instance Next Generation Sequencing (NGS)-based 
personalized therapeutic strategies. Although NGS is 
capable to identify druggable mutations in the majority 
of human cancers [76]. It is important to consider that 
driver actionable targets needs to be identified taking 
into account the general biologic scenario which can be 
disclosed only by multiple level integrated analysis. 
On the basis of our findings, HD-MM should be 
considered in clinical trial stratification. Potential targeted 
approaches should be therefore investigated for HD-
MM, for instance taking into account the nodal points 
that emerge from our integrated analysis. Moreover, we 
suggest that follow-up studies should investigate the 
prognostic/predictive value of the inferred targets in 
patient series stratified for HD molecular phenotype.
In conclusion, our study indicates that an 
integrative genomics approach can identify key URs 
based on expression profiles and on external knowledge. 
Functional studies can be now designed to provide the 
final wet biology proof of our in silico findings. It must 
be considered that the main limitation of integrative 
genomics is its inherent hypothesis generating aim. A 
strongly defined path from integrative genomics to well 
defined proof-of-concept orthogonal studies appears a 
provocative novel translational approach in MM, whose 
cure is a still unmet goal.
MATERIALS AND METHODS
Patients and miRNA and mRNA microarray data
To investigate the dynamic regulation and potential 
co-regulation of mRNAs and miRNAs, we used the MM 
miRNAs and gene expression microarray data obtained by 
the Gene Expression Omnibus (GEO). Gene expression 
profiling (GEP) were performed using the Affymetrix 
HG-133 Plus 2.0 Genechip arrays (accession number 
GSE15695) while miRNA profiles were generated by 
Affymetrix GeneChip miRNA arrays v1.0 (accession 
number GSE41276). We included in this study a total 
of 152 patients. Among them, 139 had available GEP, 
miRNA profiles and hyperdiploid status assessed by FISH 
(HD=83; nHD=56). 
Data analysis
The workflow of the data processing and analysis is 
illustrated in Figure 1. Pre-processing of microarray data 
was performed by Affymetrix® Expression ConsoleTM 
software using the RMA normalization algorithm for gene 
expression data and Affymetrix® QCTool for miRNA 
data. Then to remove the number of uninformative 
features the mRNA and miRNA expression data were 
filtered with options for logged data, by DChip® software 
obtaining a list of 517 annotated transcript and 708 hsa-
miRs, respectively. Hierarchical clustering analysis, 
using correlation as distance metric and centroid linkage, 
of the filtered genes/miRNAs was performed by DChip 
and the representation by heat map are shown in Figure 
2 and in supplementary materials. To identify significant 
differentially expressed (SDE) genes and miRNAs we 
performed comparison analysis by DChip software using 
139 MM patients where the hyperdiploid status were 
known. We searched for SDE genes/miRNAs using the 
two groups HD-MM (Experiment -E) versus nHD-MM 
(Baseline -B). The fold change (FC) was calculated as 
E-B (>+1,2) for genes and E/B (>+1,2) for miRNAs. We 
obtained a list of 39 differential expressed mRNA (SDE- 
genes) and 343 miRNAs (SDE- miRNAs), respectively. 
Ingenuity pathway analysis
Both SDE-mRNAs and SDE-miRNAs between 
HD- versus nHD-MM lists were uploaded on the IPA 
software (www.ingenuity.com, License Item Number IPA-
NUL-00001) to analyze first canonical pathways linked 
to the two distinct classes of myeloma, based on the IPA 
library of canonical pathways signaling. The statistical 
significance of the association among the experimental 
conditions and each discovered pathway was measured 
by Fisher’s exact Test. Consequently, we discarded those 
pathways with P-value higher than 0.05, ensuring that 
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the association between the genes in our data set and a 
canonical pathway was not explained by chance alone.
IPA functional analysis
To identify significant biological functions in our 
gene expression data set, we used the list of SDE genes 
and selected only biofunctions with a P-value lower than 
0.05 using the Benjamini–Hochberg correction. 
miRNA target filter
IPA stores association among miRNAs and 
their targets by integrating different sources: Tarbase, 
TargetScan and its internal findings. We uploaded SDE-
miRNAs list into IPA and then we performed miRNA 
target filtering. In order to improve the quality of results, 
we chose only experimental and high confidence predicted 
targets.
Upstream regulator analysis
The Upstream Regulator Analysis (URA) is based 
on a statistical matching that determines and ranks 
regulators that may be associated to the dataset [31]. 
The approach evaluates the relationships by using two 
measures: an overlap P-value that measures the statistical 
significance of the finding, as well as an activation 
Z-score that carries information about the strength of 
the relationship and the activation state (either activated 
or inhibited). Z-score varies in the range -2 (inhibition) 
and +2 (activation). In our data IPA upstream regulators 
analysis was performed using the SDE gene list. Results 
were sorted by statistical and biological significance 
using both P-value and Z-score. We selected the upstream 
regulators (URs) with P-value higher than 0,05 and 
Z-score +1,9. Then we performed by IPA the overlay of 
regulatory networks and bio-function.
miRNA-TR interplay
For each molecule individuated in the previous 
step, we searched for related miRNAs into the SDE-
miRNA list. In order to improve the quality of findings we 
selected only miRNAs identified as experimental or high 
score predicted for IPA. Thus, we were able to elucidate 
interplay of upstream and miRNA regulators of the same 
target.
Circos plot
We used Circos Plot to better visualize the 
correspondence among identified SDE-mRNAs, the 
related miRNA and their bio-functions [77]. Thus we 
linked each SDE-mRNA to their related miRNA and URs, 
and to the function assessed. 
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